Swedish pharmaceutical company EQL Pharma AB (STO: EQL), which specialises in developing and selling generics, said on Wednesday it has secured approval for its melatonin-based product Mellozzan in Kazakhstan through regional partner Abdi Ibrahim, a Turkish pharmaceutical company with manufacturing facilities in Türkiye, Kazakhstan and Algeria.
The authorisation currently covers the 3 mg strength, with approval for the 5 mg strength expected in December 2026. Both strengths are planned for launch in the 2027/28 fiscal year.
Mellozzan is indicated for children with ADHD experiencing sleep difficulties unresponsive to sleep-hygiene measures, and for the short-term treatment of jet lag in adults.
Kaiser Permanente reports study findings showing significant cost savings
Apotex receives Health Canada approval for a generic Ozempic equivalent
Cipla's AB-rated Ventolin HFA generic receives US FDA approval
Newbury Pharmaceuticals secures first Scandinavian approval for palbociclib generic
Apotex's generic Ozempic (Semaglutide Injection) receives US FDA tentative approval
DifGen and Apotex report FDA approval of generic Nintedanib Soft Gel Capsules
Dexcel Pharma's Nintedanib Capsules approved for US launch
Upsher-Smith launches generic version of Ciprodex ear drop suspension
Samsung Bioepis partners with Sandoz on up to five next-generation biosimilars
Breckenridge Pharmaceutical partners with sterile injectable manufacturer Maiva Pharma
Breckenridge Pharmaceutical launches Pomalidomide Capsules in US market
Cipla launches generic liraglutide injection in the US
Arna Pharma signs MOU with Slate Run Pharmaceuticals
STADA and Bio-Thera Solutions receive European marketing authorisation for Gotenfia (golimumab)